Drug intelligence / Profile preview

Progyn

Development stage: Unknown
Lead developer: Astel Medica
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

Progyn is an oral probiotic dietary supplement developed by Astel Medica specifically for women's intimate health and wellbeing. It is formulated as a capsule containing three specific strains of lactobacilli: *Lactobacillus brevis* PHA-131 (80 mg), *Lactobacillus acidophilus* PHA-122 (80 mg), and *Lactobacillus rhamnosus* PHA-152 (40 mg), providing approximately 2.5 billion live bacteria per capsule at production. The formulation also includes 20 mg of FructoOligoSaccharide (FOS), which acts as a prebiotic to support the growth of beneficial bacteria. Progyn is designed to restore and maintain the natural vaginal flora, ensuring intimate balance. It is marketed as a well-tolerated product suitable for use during pregnancy and breastfeeding.

Brand names: Progyn

Beyond the preview

Go deeper on Progyn.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Progyn.

Explore the full profile